The program featured an international, expert faculty presenting recent research in areas such as disease pathophysiology, novel treatment modalities, clinical considerations for future trials. As per all Magdalen Scientific run events, the program was comprised of concise presentations complemented by time for in-depth group discussions. We have found that this approach helps to foster innovation and enables faculty to translate insights into actionable strategies for practice-changing progress.

A particular highlight of this year’s meeting was during the Immuno- and targeted therapies and data in high risk session, where Drs Chari, Joseph and Vorhees presented novel data on recent progress to help manage and mitigate risk HRMM. To watch the workshop presentations, along with exclusive roundtable discussions captured by VJHemOnc , click here .

Meeting chair Dr Saad Usmani said, “This year, it’s been an outstanding meeting… many good ideas have already come out, so we’re really looking forward to working on those ideas and coming back next year and sharing with the rest of the group”. To watch his interview in full, click here .

iwHRMM 2025 was made possible through the generous support of its industry partners. Thanks to GSK, Johnson & Johnson, Legend Biotech, Regeneron, Sanofi, K36 Therapeutics, SkylineDx, and Kite, a Gilead Company & Arcellx for their sponsorship.

The success of this year’s workshop has once again highlighted the importance of sustained dialogue and collective effort in moving the field forward. Magdalen Scientific is therefore pleased to announce that iwHRMM will return in 2026 for its third year, taking place 21–23 October in Charleston, South Carolina.

For more information about iwHRMM, please visit: https://iwhrmm.org/ . If you would like to speak to a member of the team, contact us .